Risk Factors for the Development of Secondary Malignancy After High-Dose Chemotherapy and Autograft, With or Without Rituximab: A 20-Year Retrospective Follow-Up Study in Patients With LymphomaCorrado Tarella, Alessandro Rambaldi, Alessandro M. Gianni et al.|Journal of Clinical Oncology|2010Cited by 167
The lymphocyte to monocyte ratio improves the IPI‐risk definition of diffuse large B‐cell lymphoma when rituximab is added to chemotherapyAlessandro Rambaldi, Corrado Tarella, Cristina Boschini et al.|American Journal of Hematology|2013Cited by 65
Exploiting MYC-induced PARPness to target genomic instability in multiple myelomaDaniele Caracciolo, Pierfrancesco Tassone|Haematologica|2020Cited by 51
Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter StudyMarco Ruella, Liliana Devizzi, Andrea Riccardo Filippi et al.|International Journal of Radiation Oncology*Biology*Physics|2015Cited by 48
Rate of Primary Refractory Disease in B and T-Cell Non-Hodgkin’s Lymphoma: Correlation with Long-Term SurvivalCorrado Tarella, Alessandro Rambaldi, Angela Gueli et al.|PLoS ONE|2014Cited by 26